Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

A randomized, double-blind, placebo-controlled phase I trial was conducted in 32 HIV-uninfected healthy volunteers to assess the safety and immunogenicity of 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC-M4) or 3 doses of TBC-M4 alone (groups A a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hayes, Peter, Gilmour, Jill, von Lieven, Andrea, Gill, Dilbinder, Clark, Lorna, Kopycinski, Jakub, Cheeseman, Hannah, Chung, Amy, Alter, Galit, Dally, Len, Zachariah, Devika, Lombardo, Angela, Ackland, James, Sayeed, Eddy, Jackson, Akil, Boffito, Marta, Gazzard, Brian, Fast, Patricia E., Cox, Josephine H., Laufer, Dagna
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2013
Materias:
Vaccines
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3592345/
https://ncbi.nlm.nih.gov/pubmed/23345581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00637-12
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares